Vivera Pharmaceuticals has announced the introduction of two new diagnostic tests for the detection of SARS-CoV-2 antigens in those with active infections from nasal or saliva specimens.

Vivera's COVx-RDA Antigen Test Saliva Collection Kit and COVx-RDA Antigen Test Nasal Collection Kit for SARS-CoV-2 are designed for rapid detection in high volume environments requiring highly accurate test results. 

Vivera's new antigen tests are relatively easy to use and with results in 10 minutes, remove barriers to diagnosing acute infection.

Complimentary to Vivera's antigen test kits are the rRT-PCR and antibody tests also made available Vivera.

Vivera's RT-PCR test is also a molecular diagnostic test for COVID-19 while Vivera's serological antibody test can help identify antibodies in individuals, indicative of an active or prior infection.   

"Antibody tests are ideal for high volume screening, where infection numbers are declining. PCR and Antigen testing are designed for high volume testing where there are suspected outbreaks or increasing infection numbers," said Dr Stephen McColgan, Vivera Pharmaceuticals' Chief Medical Officer.

Vivera's COVx-RDA test kits are ready for use by laboratories and medical facilities immediately. 

Both the COVx-RDA Saliva Collection and COVx-RDA Nasal Collection test kits have undergone extensive validation testing, and Emergency Use Authorization applications are being filed with the FDA. The tests will be available for use by CLIA-certified laboratories and medical professionals.